865 - 876 of 7601 results

Heart Failure with Preserved Ejection Fraction (HFpEF): Pathophysiology vs Outcomes Are We Narrowing the Gap?

Industry Webcast Sponsored by Novartis Pharmaceuticals Corporation; Not for CME/CE Credit

Heart failure with preserved ejection fraction (HFpEF) is a complex disease with pathophysiological heterogeneity, whose treatment is primarily focused on management of symptoms vs treatment of the underlying disease. This talk will highlight some of the multiple pathways being explored in the attempt to bridge the gap between managing comorbidities/symptoms and treating the disease itself.


Act Now: Simple Steps to Shingles Prevention

0.50 CME
0.40 AANP | 0.27 Pharmacology

Because cell-mediated immunity declines with age, individuals aged 50 years and older are at increased risk for the reactivation of the latent varicella zoster virus that causes shingles. Learn about vaccination recommendations to prevent shingles and complications of herpes zoster, especially postherpetic neuralgia. Answer questions about shingles prevention and win at Jeopardy!


In the past few years, there have been major advances in the acute treatment of migraine. Multiple medications and devices have recently received FDA-approval, filling some of the unmet treatment needs for patients with migraine. Join primary care physician Dr. Susan Burke and headache specialist Dr. Stewart Tepper, as they review acute treatment strategies and compare older medications with the newer options, including CGRP antagonists, a serotonin 5-HT1F receptor antagonist, and neuromodulation devices. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 8/31/2020 and they are subject to change as new information is published.

computer drawing of a heart

Primary Care Heart Failure Learning Module

An Adaptive Learning Experience Sponsored by Novartis Pharmaceuticals Corporation; Not for CME/CE Credit

Heart failure (HF) is a complex syndrome brought on by impairment of the structure or function of ventricular filling or blood ejection. These changes can significantly decrease quality of life, resulting in edema, dyspnea, and fatigue. The disease is widespread and progresses in severity, resulting in significant morbidity and mortality. This course is built on the latest HF guidelines and seeks to help learners better understand this prevalent, serious disease. Topics include pathophysiology, etiology, and epidemiology, morbidity and mortality, diagnosis through the use of biomarkers and other screening tools, impact of HF hospitalization, hospitalization care goals and team-based care.


Watch this virtual patient case study involving sequential telemedicine encounters between noted neurologist, Dr. Rashmi Halker Singh, and a young woman with 10 years of migraine whose attacks have recently worsened. Through the telemedicine encounters, Dr. Halker Singh provides practical tips about assessment and individualized treatment, including pharmacologic therapy and patient self-management strategies to optimize chronic migraine management.


This patient case follows the course of a young woman who presents with a complaint of recurrent “sinus” headaches. You will review the proper diagnosis of migraine and, through a series of encounters with the patient, learn to individualize management of episodic migraine, including the use of acute pharmacologic treatment options. Please note that any data, indications, and guidelines presented in this activity are current as of the posting on 6/18/2020 and they are subject to change as new information is published.

Learn More Breathe Better

Leader in Continuing Medical Education Joins Federal Effort to Promote Latest Clinical Insights

Management of Osteoarthritis and Chronic Pain: Where Are We Now?

Industry Webcast Sponsored by Pfizer and Eli Lilly and Company; Not for CME/CE Credit

This presentation will provide an overview of the epidemiology and treatment of osteoarthritis (OA) and chronic OA pain. We will review the current understanding of chronic pain pathophysiology – the various mediators, their role in central and peripheral sensitization, and the nociceptive components of chronic OA pain. We will also examine current OA treatment guidelines and explore “multimodal” treatment options, with a focus on working with patients toward individual treatment goals, and the establishment of holistic management strategies for patients with chronic OA pain.


New-onset Atrial Fibrillation: Revisiting Rate vs. Rhythm Control - Frankly Speaking EP 205

Guest: Alan Ehrlich, MD, FAAFPMusic Credit: Richard Onorato

0.25 CME

In patients with new-onset atrial fibrillation, the decision to aim for rate control versus rhythm control is controversial. Older data suggested rhythm control did not result in better outcomes, but advances in medications and techniques have led to a new trial to evaluate this question.


No Good Reason to Go Nuts Over Coconut Oil - Frankly Speaking EP 203

Guest: Jill Terrien, PhD, ANP-BCMusic Credit: Richard Onorato

0.25 CME

Join us as we discuss the risks of elevated cholesterol when consuming coconut oil.

woman examines her incontinence brief

Curb the Urge: Overactive Bladder for Primary Care

An Interactive Video Experience

1.00 CME/MOC
1.00 AANP | 0.33 Pharmacology

Experience this interactive video-based activity designed to increase your knowledge of the diagnosis and management of overactive bladder, a common condition that can have a devastating adverse effect on patients’ quality of life. Join expert faculty as they discuss OAB through a combination of video, quiz-questions, pop-up teaching points, and downloadable resources. Learn the latest guideline recommendations for OAB testing and treatment and review non-pharmacologic management options as well as the indications, safety, and efficacy of currently available medications. Through this activity, you will have access to a robust resource library, including slides, abstracts, and practice tools selected by the faculty, and which can be downloaded for future reference.

Jardiance<sup>®</sup> (empagliflozin) tablets

To learn more about JARDIANCE safety and efficacy data as well as information about initiating JARDIANCE in your patients, please access the below link.                                                                                                                                                                                    www.JARDIANCELectureSeries.com                                                                                                                                                                               Copyright © 2020 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved. (11/20) EM-US-101640